Clinical Trial Update: Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating intensity-modulated radiation therapy with pemetrexed and erlotinib in recurrent or second primary head and neck cancer; study termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Intensity-Modulated Radiation Therapy
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-12-13